Intravenous Granulocyte Colony-Stimulating Factor Administration Can Attenuate Neuropathic Pain Following Spinal Cord Injury in Male Rats

Authors
L Farsi, M Keshavarz, K Afshari, AN Javidan


Lab
Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Journal
Acta Medica Iranica

Abstract
Peripheral neuropathy, regularly expressed as hypersensitivity to painful stimuli, is between the most common complications of spinal cord injury (SCI) that develops in up to 40% of patients and appears to be persistent. Previous studies have demonstrated neuroprotective effects of Granulocyte colony-stimulating factor (G-CSF) on neuropathic pains. We aimed to investigate the antihyperalgesic effect of G-CSF on neuropathic pains following SCI in male rats. Twenty four adult male rats (weight 300–350g) were used. After laminectomy, complete SCI was performed by compression of the spinal cord for 1 minute with an aneurysm clip. Within 30 minutes after the surgery, 200 _g/kg G-CSF was injected intravenously in G-CSF treated groups and then was repeated in 3 consecutive days. Tail flick latency (TFL), acetone drop test scores, BBB test scores, and Von-Frey filament test were performed before surgery and once a week after surgery. Rats in G-CSF treated group showed significantly higher mean TFL, and lower mean score of acetone test compared with those in SCI+veh group 4 weeks after surgery (P<0.05). There was no significant difference between rats in G-CSF treated group and SCI+veh group in BBB and Von-Frey filament tests results. These findings revealed that treatment with systemic administration of intravenous G-CSF would attenuate thermal hyperalgesia, and cold allodynia induced by SCI in rats but has no significant effect on locomotor activity and mechanical allodynia after SCI.

BIOSEB Instruments Used:
Von Frey Filaments (Bio-VF-M)

Related products

Publication request

Thank you for your interest in our product range and your request for this publication, which will be sent to you if the research team and the journal allow it. Our commercial team will contact you as soon as possible.